Sit back and listen to 23andMe CEO and Co-Founder Anne Wojcicki along with 23andMe board member and founder of 23andMe Therapeutics division Richard Scheller, speak to Roelof Botha of Sequoia Capital about the critical moments in the company’s history.
Botha, who is also on the 23andMe Board of Directors, dives into how the company weathered early criticism even at its founding in 2006, to the 2013 FDA letter that ordered 23andMe to stop selling health testing products to customers, to downturns in consumer interest.
The episode is part of a series called Crucible Moments, produced by Sequoia Capital. In this series Roelof explores moments in every start-up business journey in which a company can succeed or fail. How a company responds often defines its future.
Take a listen and learn a little about 23andMe’s history.